A clinical case of successful application of a new treatment method for severe COVID-19

Abstract

COVID-19, formerly coronavirus infection 2019-nCoV, is a potentially severe acute respiratory infection caused by the SARS-CoV-2 coronavirus (2019-nCoV). It is a dangerous disease that can occur both in the form of a mild acute respiratory viral infection and in a severe form with the development of bilateral polysegmental viral pneumonia, specific complications of which may include acute respiratory distress syndrome, resulting in the respiratory failure with a high risk of death. Due to the absence of etiotropic therapy for the coronavirus infection, pathogentic treatment becomes of primary importance. We present a clinical case of a severe form of COVID-19 in a 33-year-old man to whom we administered a new method of pathogenetic treatment of this disease based on immunosuppresiive therapy followed by therapeutic plasma exchange and infusion of non-specific human immunoglobulin.

Keywords

COVID-19 / selective plasma filtration / immunosuppression / plasma exchange / case report

References

[1] ВОЗ. Клиническое руководство по ведению пациентов с тяжелой острой респираторной инфекцией при подозрении на инфицирование новым коронавирусом (2019-nCoV). Временное руководство от 28 января 2020 г. WHO/nCoV/Clinical/2020.2 [интернет]. [Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance 28 January 2020. WHO/nCoV/Clinical/2020.2 [Internet]. (In Russ).] Доступно по: https://webmaster.yandex.ru/siteinfo/?site=www.rospotrebnadzor.ru. Ссылка активна на 16.05.2020.

[2] Роспотребнадзор. Рекомендации ВОЗ для населения в связи c распространением нового коронавируса (2019-nCoV): мифы и ложные представления [интернет]. [Rospotrebnadzor. Rekomendatsii VOZ dlya naseleniya v svyazi c rasprostraneniyem novogo koronavirusa (2019-nCoV): mify i lozhnyye predstavleniya [Internet]. (In Russ).] Доступно по: https://www.rospotrebnadzor.ru/region/rss/rss.php?ELEMENT_ID=13990. Ссылка активна на 16.05.2020.

[3] Bassetti M, Vena A, Giacobbe DR. The novel chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest. 2020;50(3):e13209. doi: 10.1111/eci.13209.

[4] Beeching, Fletcher, Fowler, 2020, Prognosis, Case fatality rate. Available from: https://www.semanticscholar.org/paper/The-novel-Chinese-coronavirus-(2019-nCoV)-for-the-Bassetti-Vena/d3373cd7db828a91a2709ea8fbec7d6776b6f42f

[5] Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72. doi: 10.1086/511159.

[6] Faqihi F, Alharthy A, Alodat M, et al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol. Trials. 2020;21:506. doi: 10.1186/s13063-020-04454-4.

[7] Hua Shi, Chaomin Zhou, Pinghong He, et al. . Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. Int J Antimicrob Agents. 2020;105974. doi: 10.1016/j.ijantimicag.2020.105974.

[8] Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses — a statement of the Coronavirus Study Group. bioRxiv. 2020. doi: 10.1101/2020.02.07.937862.

[9] Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71. doi: 10.5582/bst.2020.01020.

[10] Zhang J, Zhou L, Yang Yu, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8(3):e11–e12. doi: 10.1016/S2213-2600(20)30071-0.

[11] Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34(2):75–80. doi: 10.1016/j.tmrv.2020.02.003.

[12] Распоряжение Правительства РФ от 12 октября 2019 г. № 2406-р. [Order of the Government of the Russian Federation № 2406-r dated 2019 October 12. (In Russ).] Доступно по: https://www.garant.ru/products/ipo/prime/doc/72761778/. Ссылка активна на 20.04.2020.

[13] Диагностика и интенсивная терапия острого респираторного дистресс-синдрома. (In Russ).] Доступно по: http://www.far.org.ru/recomendation

Funding

Федеральное медико-биологическое агенство РоссииFederal Medical and Biological Agency of Russia

RIGHTS & PERMISSIONS

Samoylov A.S., Udalov Y.D., Kruglyakov N.M., Terekhov D.А., Bagzhanov G.I., Ochkin S.S.